AnaptysBio (NASDAQ:ANAB) Lifted to Neutral at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of AnaptysBio (NASDAQ:ANAB – Get Rating) from an underweight rating to a neutral rating in a report issued on Monday morning, The Fly reports. They currently have $30.00 price objective on the biotechnology company’s stock, down from their prior price objective of $31.00.

ANAB has been the topic of a number of other research reports. Guggenheim boosted their price objective on shares of AnaptysBio from $44.00 to $45.00 in a report on Friday, May 12th. TD Cowen began coverage on shares of AnaptysBio in a report on Thursday, May 18th. They set an outperform rating on the stock. Finally, StockNews.com began coverage on shares of AnaptysBio in a report on Thursday, May 18th. They issued a hold rating on the stock. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Hold and an average target price of $34.67.

AnaptysBio Stock Down 1.5 %

Shares of AnaptysBio stock opened at $18.64 on Monday. AnaptysBio has a 52-week low of $18.03 and a 52-week high of $32.44. The company’s 50-day simple moving average is $21.08 and its 200-day simple moving average is $24.68. The firm has a market cap of $493.77 million, a price-to-earnings ratio of -3.85 and a beta of -0.16.

AnaptysBio (NASDAQ:ANAB – Get Rating) last issued its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.54). The firm had revenue of $1.37 million for the quarter, compared to analyst estimates of $4.02 million. AnaptysBio had a negative return on equity of 52.83% and a negative net margin of 1,278.87%. Equities research analysts anticipate that AnaptysBio will post -6.42 EPS for the current year.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new stake in shares of AnaptysBio in the second quarter worth $34,000. US Bancorp DE increased its position in shares of AnaptysBio by 44.4% in the third quarter. US Bancorp DE now owns 1,538 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 473 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of AnaptysBio by 75.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 2,142 shares in the last quarter. Fred Alger Management LLC acquired a new stake in shares of AnaptysBio in the fourth quarter worth $191,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of AnaptysBio in the third quarter worth $211,000.

AnaptysBio Company Profile

(Get Rating)

AnaptysBio, Inc is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro.